Inspire Pharma: Dry-Eye Treatment Didn't Meet Study Endpoints

trial. Shares fell 7.5% to $6.11 premarket. Shares in its partner in developing the eye drops, Allergan Inc. (AGN), weren't active after closing Wednesday at $ 61.20. Early data about Prolacria had been discouraging, so the final results won't come as a...